132 related articles for article (PubMed ID: 36453216)
1. Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis.
Choo BP; Goh GBB; Chia SY; Oh HC; Tan NC; Tan JYL; Ang TL; Bee YM; Wong YJ
Ann Acad Med Singap; 2022 Nov; 51(11):686-694. PubMed ID: 36453216
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
Sangha K; Chang ST; Cheung R; Deshpande VS
Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
Vilar-Gomez E; Lou Z; Kong N; Vuppalanchi R; Imperiale TF; Chalasani N
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2305-2314.e12. PubMed ID: 32289535
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness study of FIB-4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at-risk population.
Park H; Yoon EL; Kim M; Kwon SH; Kim D; Cheung R; Kim HL; Jun DW
Liver Int; 2024 Apr; 44(4):944-954. PubMed ID: 38291809
[TBL] [Abstract][Full Text] [Related]
6. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
Tapper EB; Hunink MG; Afdhal NH; Lai M; Sengupta N
PLoS One; 2016; 11(2):e0147237. PubMed ID: 26905872
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting.
Vieira Barbosa J; Lai M
Hepatol Commun; 2021 Feb; 5(2):158-167. PubMed ID: 33553966
[TBL] [Abstract][Full Text] [Related]
9. Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
Cassinotto C; Boursier J; Paisant A; Guiu B; Irles-Depe M; Canivet C; Aube C; de Ledinghen V
Hepatology; 2021 Jun; 73(6):2196-2205. PubMed ID: 33236409
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
Mózes FE; Lee JA; Selvaraj EA; Jayaswal ANA; Trauner M; Boursier J; Fournier C; Staufer K; Stauber RE; Bugianesi E; Younes R; Gaia S; Lupșor-Platon M; Petta S; Shima T; Okanoue T; Mahadeva S; Chan WK; Eddowes PJ; Hirschfield GM; Newsome PN; Wong VW; de Ledinghen V; Fan J; Shen F; Cobbold JF; Sumida Y; Okajima A; Schattenberg JM; Labenz C; Kim W; Lee MS; Wiegand J; Karlas T; Yılmaz Y; Aithal GP; Palaniyappan N; Cassinotto C; Aggarwal S; Garg H; Ooi GJ; Nakajima A; Yoneda M; Ziol M; Barget N; Geier A; Tuthill T; Brosnan MJ; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
Gut; 2022 May; 71(5):1006-1019. PubMed ID: 34001645
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study.
Mettananda C; Egodage T; Dantanarayana C; Fernando R; Ranaweera L; Luke N; Ranawaka C; Kottahachchi D; Pathmeswaran A; de Silva HJ; Dassanayake AS
BMJ Open; 2023 Jan; 13(1):e063959. PubMed ID: 36639212
[TBL] [Abstract][Full Text] [Related]
12. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
[TBL] [Abstract][Full Text] [Related]
13. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
Congly SE; Shaheen AA; Swain MG
PLoS One; 2021; 16(5):e0251741. PubMed ID: 34019560
[TBL] [Abstract][Full Text] [Related]
14. Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD.
Al-Karaghouli M; Fuentes S; Davyduke T; Ma M; Abraldes JG
BMJ Open Gastroenterol; 2022 Jan; 9(1):. PubMed ID: 34992072
[TBL] [Abstract][Full Text] [Related]
15. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
[TBL] [Abstract][Full Text] [Related]
16. Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care.
Davyduke T; Tandon P; Al-Karaghouli M; Abraldes JG; Ma MM
Hepatol Commun; 2019 Oct; 3(10):1322-1333. PubMed ID: 31592044
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of nonalcoholic steatohepatitis screening.
Zhang E; Wartelle-Bladou C; Lepanto L; Lachaine J; Cloutier G; Tang A
Eur Radiol; 2015 Nov; 25(11):3282-94. PubMed ID: 25994191
[TBL] [Abstract][Full Text] [Related]
20. Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface.
McPherson S; Jarvis H; McGonigle J; Bedlington J; Dean J; Hallsworth K; Hanon E; Liddle T; Luvai A; Mansour D; Patel P; Renwick L; Teare D; Tanney C; Anstee Q
BMJ Open Gastroenterol; 2023 Feb; 10(1):. PubMed ID: 36754448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]